Latest news
HBM Holdings (SEHK:2142) Names Metabolic Chief And Partners With Sinopharm, Is It Fully Priced? - simplywall.stsimplywall.st · Sun, 09 Aug 2026 11:31:03 GMTHK Stock Market Movers | Harbour BioMed-B (02142) Rises Over 7% in Early Trading, Reports Revenue Growth and Profitability for First Half, Recently Entered Strategic Partnership with Sinopharm Group - MoomooMoomoo · Fri, 07 Aug 2026 02:49:29 GMTHarbour BioMed Names Dr. Bob Zhang to Lead Metabolic Disease Franchise Expansion - citybizcitybiz · Thu, 06 Aug 2026 13:45:56 GMTHBM Holdings Limited (2142.HK) stock price, news, quote and history - Yahoo Finance UKYahoo Finance UK · Thu, 06 Aug 2026 11:39:16 GMTHarbour BioMed Appoints Dr. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative Therapies - PR NewswirePR Newswire · Thu, 06 Aug 2026 08:10:00 GMTHarbour BioMed appoints Bob Zhang as President of Metabolic Disease Franchise - scanx.tradescanx.trade · Thu, 06 Aug 2026 07:00:00 GMTHarbour BioMed and Kelun-Biotech receive China IND approval for bispecific asthma therapy - BioSpectrum AsiaBioSpectrum Asia · Mon, 03 Aug 2026 10:41:15 GMTHBM Holdings (SEHK:2142) Teams Up With Sinopharm To Build A Biologics Consortium - Yahoo FinanceYahoo Finance · Wed, 29 Jul 2026 07:00:00 GMT